Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OST-664
- Development stage
- Unknown
- Lead developer
- Oncostellae
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OST-664 is an oral small molecule inhibitor of NUAK family kinase 1 (NUAK1), also known as AMPK-related protein kinase 5 (ARK5). Developed by the Spanish biopharmaceutical company Oncostellae, the compound is specifically designed to target the biological pathways involved in fibrotic processes. ARK5 is a member of the AMPK-related kinase family and plays a role in cellular stress responses, metabolic regulation, and cytoskeletal dynamics. By inhibiting ARK5, OST-664 aims to disrupt the signaling cascades that drive the progression of fibrosis. The drug is currently in early clinical development (Phase 1/2) for the treatment of various fibrotic conditions.
02
Targets
NUAK1 (NUAK family SNF1-like kinase 1)
Beyond the preview
Go deeper on OST-664.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OST-664.